259 related articles for article (PubMed ID: 36354092)
1. Ketamine and its metabolites: Potential as novel treatments for depression.
Zhang K; Yao Y; Hashimoto K
Neuropharmacology; 2023 Jan; 222():109305. PubMed ID: 36354092
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of ketamine and its metabolites as antidepressants.
Hess EM; Riggs LM; Michaelides M; Gould TD
Biochem Pharmacol; 2022 Mar; 197():114892. PubMed ID: 34968492
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of ketamine action as an antidepressant.
Zanos P; Gould TD
Mol Psychiatry; 2018 Apr; 23(4):801-811. PubMed ID: 29532791
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine.
Hashimoto K
Biochem Pharmacol; 2020 Jul; 177():113935. PubMed ID: 32224141
[TBL] [Abstract][Full Text] [Related]
5. Activity-dependent brain-derived neurotrophic factor signaling is required for the antidepressant actions of (2
Fukumoto K; Fogaça MV; Liu RJ; Duman C; Kato T; Li XY; Duman RS
Proc Natl Acad Sci U S A; 2019 Jan; 116(1):297-302. PubMed ID: 30559184
[TBL] [Abstract][Full Text] [Related]
6. (
Zanos P; Highland JN; Stewart BW; Georgiou P; Jenne CE; Lovett J; Morris PJ; Thomas CJ; Moaddel R; Zarate CA; Gould TD
Proc Natl Acad Sci U S A; 2019 Mar; 116(13):6441-6450. PubMed ID: 30867285
[TBL] [Abstract][Full Text] [Related]
7. Ketamine: A tale of two enantiomers.
Jelen LA; Young AH; Stone JM
J Psychopharmacol; 2021 Feb; 35(2):109-123. PubMed ID: 33155503
[TBL] [Abstract][Full Text] [Related]
8. NMDAR inhibition-independent antidepressant actions of ketamine metabolites.
Zanos P; Moaddel R; Morris PJ; Georgiou P; Fischell J; Elmer GI; Alkondon M; Yuan P; Pribut HJ; Singh NS; Dossou KS; Fang Y; Huang XP; Mayo CL; Wainer IW; Albuquerque EX; Thompson SM; Thomas CJ; Zarate CA; Gould TD
Nature; 2016 May; 533(7604):481-6. PubMed ID: 27144355
[TBL] [Abstract][Full Text] [Related]
9. Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites.
Yang C; Yang J; Luo A; Hashimoto K
Transl Psychiatry; 2019 Nov; 9(1):280. PubMed ID: 31699965
[TBL] [Abstract][Full Text] [Related]
10. Ketamine and the Future of Rapid-Acting Antidepressants.
Riggs LM; Gould TD
Annu Rev Clin Psychol; 2021 May; 17():207-231. PubMed ID: 33561364
[TBL] [Abstract][Full Text] [Related]
11. Beyond Ketamine: New Approaches to the Development of Safer Antidepressants.
Chaki S
Curr Neuropharmacol; 2017; 15(7):963-976. PubMed ID: 28228087
[TBL] [Abstract][Full Text] [Related]
12. AMPA Receptor Activation-Independent Antidepressant Actions of Ketamine Metabolite (S)-Norketamine.
Yang C; Kobayashi S; Nakao K; Dong C; Han M; Qu Y; Ren Q; Zhang JC; Ma M; Toki H; Yamaguchi JI; Chaki S; Shirayama Y; Nakazawa K; Manabe T; Hashimoto K
Biol Psychiatry; 2018 Oct; 84(8):591-600. PubMed ID: 29945718
[TBL] [Abstract][Full Text] [Related]
13. The role of eEF2 kinase in the rapid antidepressant actions of ketamine.
Suzuki K; Monteggia LM
Adv Pharmacol; 2020; 89():79-99. PubMed ID: 32616215
[TBL] [Abstract][Full Text] [Related]
14. Convergent Mechanisms Underlying Rapid Antidepressant Action.
Zanos P; Thompson SM; Duman RS; Zarate CA; Gould TD
CNS Drugs; 2018 Mar; 32(3):197-227. PubMed ID: 29516301
[TBL] [Abstract][Full Text] [Related]
15. Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective.
Hashimoto K
Psychiatry Clin Neurosci; 2019 Oct; 73(10):613-627. PubMed ID: 31215725
[TBL] [Abstract][Full Text] [Related]
16. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
[TBL] [Abstract][Full Text] [Related]
17. Role of the AMPA receptor in antidepressant effects of ketamine and potential of AMPA receptor potentiators as a novel antidepressant.
Suzuki A; Hara H; Kimura H
Neuropharmacology; 2023 Jan; 222():109308. PubMed ID: 36341809
[TBL] [Abstract][Full Text] [Related]
18. (S)-norketamine and (2S,6S)-hydroxynorketamine exert potent antidepressant-like effects in a chronic corticosterone-induced mouse model of depression.
Yokoyama R; Higuchi M; Tanabe W; Tsukada S; Naito M; Yamaguchi T; Chen L; Kasai A; Seiriki K; Nakazawa T; Nakagawa S; Hashimoto K; Hashimoto H; Ago Y
Pharmacol Biochem Behav; 2020 Apr; 191():172876. PubMed ID: 32088360
[TBL] [Abstract][Full Text] [Related]
19. Role of neurotrophic and growth factors in the rapid and sustained antidepressant actions of ketamine.
Deyama S; Kaneda K
Neuropharmacology; 2023 Feb; 224():109335. PubMed ID: 36403852
[TBL] [Abstract][Full Text] [Related]
20. Is the History Repeated? Can (2
Chaki S; Yamaguchi JI
J Exp Neurosci; 2018; 12():1179069518815445. PubMed ID: 30573991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
